CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

Core Insights - Cadrenal Therapeutics is developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, aimed at providing safer chronic anticoagulation for patients with implanted cardiac devices, particularly those with left ventricular assist devices (LVADs) [1][4] - A presentation at the EACTS Mechanical Circulatory Support Summit highlighted tecarfarin's historical data and a proposed clinical trial protocol to evaluate its effectiveness compared to warfarin in patients using the Abbott HeartMate3 LVAD [1][2] Company Overview - Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on tecarfarin, which is expected to result in fewer adverse events compared to warfarin, including strokes, heart attacks, and bleeding [4] - The company has received orphan drug designation for advanced heart failure patients with LVADs and fast-track status for end-stage kidney disease patients with atrial fibrillation [4] Clinical Trial Insights - The proposed TECH-LVAD trial aims to study tecarfarin's potential to reduce bleeding events associated with the use of the HM3 LVAD in advanced heart failure patients [3] - Historical data presented indicated an inverse relationship between bleeding rates and time in therapeutic range (TTR) for HM3 patients, suggesting tecarfarin may improve TTR [2][3] Future Plans - Cadrenal is actively engaging with the FDA and Abbott to advance the tecarfarin study in LVAD patients, with plans for investigator outreach and patient recruitment [3] - The company is also exploring pivotal clinical trials and potential partnerships to further develop tecarfarin for patients with mechanical heart valves facing anticoagulation challenges [4]